Compare Vanguard International High Dividend Yield ETF (VYMI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard International High Dividend Yield ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 2.3× State Street SPDR S&P Biotech ETF's market cap, and Vanguard International High Dividend Yield ETF is more actively traded (748,441 versus 12,903,266). Which is the better fit depends on your goals — on Pluang, investors hold Vanguard International High Dividend Yield ETF for 50 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VYMI | XBI | |
|---|---|---|
Market Cap | $22.80B | $10.11B |
Volume | 748,441 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $107.13 | $169.55 |
52-Week Low | $82.92 | $104.99 |
Typical Hold Time | 50 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYMI trades at $100.06, down 0.17% with bearish technical signals from moving averages. The ETF shows strong institutional interest with recent stake increases from Envestnet and Corient Private Wealth. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with lower fees. The fund's heavy financial sector exposure (43.6%) benefits from rising global interest rates.
VYMI presents a compelling international dividend growth opportunity with attractive valuation and income characteristics. Key risks include concentration in financials and sensitivity to global economic conditions. The ETF's low 0.07% expense ratio and strong historical performance support its appeal for income-focused investors seeking international diversification.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
